APA (7th ed.) Citation

Stewart, C., Bhangu, J. S., Swarnkar, P. K., Rifat, M., Khalid, S., Al-Janabi, A., . . . Williams, G. S. (2026). Real-World Outcomes of Switching to Faricimab in Treatment-Experienced and Resistant Neovascular Age-Related Macular Degeneration: A Single-Centre Retrospective Study. Clinical Ophthalmology, 20, 1. https://doi.org/10.2147/OPTH.S591029

Chicago Style (17th ed.) Citation

Stewart, Christopher, Jaskaran Singh Bhangu, Parinita Keshav Swarnkar, Mohammed Rifat, Sarah Khalid, Ahmed Al-Janabi, Mahmoud H. Awad, and Gwyn Samuel Williams. "Real-World Outcomes of Switching to Faricimab in Treatment-Experienced and Resistant Neovascular Age-Related Macular Degeneration: A Single-Centre Retrospective Study." Clinical Ophthalmology 20 (2026): 1. https://doi.org/10.2147/OPTH.S591029.

MLA (9th ed.) Citation

Stewart, Christopher, et al. "Real-World Outcomes of Switching to Faricimab in Treatment-Experienced and Resistant Neovascular Age-Related Macular Degeneration: A Single-Centre Retrospective Study." Clinical Ophthalmology, vol. 20, 2026, p. 1, https://doi.org/10.2147/OPTH.S591029.